SXTP Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.980

Open

1.960

VWAP

1.90

Vol

63.89K

Mkt Cap

3.28M

Low

1.850

Amount

121.60K

EV/EBITDA(TTM)

--

Total Shares

--

EV

9.24M

EV/OCF(TTM)

--

P/S(TTM)

1.92

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Show More

Events Timeline

(ET)

2026-02-02

08:20:00

60 Degrees Pharmaceuticals Partners with GoodRx for Up to 30% Savings on Arakoda

2026-01-28 (ET)

2026-01-28

08:10:00

60 Degrees Pharmaceuticals Secures Exclusive License with FSU

2026-01-22 (ET)

2026-01-22

08:30:00

60 Degrees Pharmaceuticals Partners with Runway Health to Promote ARAKODA

2025-12-29 (ET)

2025-12-29

08:10:00

60 Degrees Pharmaceuticals Finds 24% of Chronic Fatigue Patients Infected with Babesia

2025-12-11 (ET)

2025-12-11

08:20:00

60 Degrees Pharmaceuticals Expands Sales and Marketing Initiatives

2025-11-21 (ET)

2025-11-21

08:14:57

60 Degrees Reveals Central Location for B-FREE Study Now Accepting Patient Enrollments

News

Benzinga

U.S. Stocks Rise in Morning Trading, Dow Up Over 100 Points

Benzinga

Baker Hughes Q4 Earnings Exceed Expectations

Benzinga

Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%

stocktwits

01-22stocktwits

60 Degrees Pharmaceuticals (SXTP) Partners with Runway Health to Launch Arakoda, Stock Surges 161%

Benzinga

Procter & Gamble (PG) Stock Rises 2% After Beating EPS Estimates in Mixed Q2 Results

NASDAQ.COM

01-16NASDAQ.COM

60 Degree Pharmaceuticals (SXTP) Announces 1-for-4 Reverse Stock Split to Regain Nasdaq Compliance

1 Analyst Rating

Wall Street analysts forecast SXTP stock price to rise

0 Buy

1 Hold

0 Sell

Hold

Current: 0.000

Low

3.40

Averages

3.40

High

3.40

Current: 0.000

Low

3.40

Averages

3.40

High

3.40

H.C. Wainwright

H.C. Wainwright

upgrade

$6 -> $24

AI Analysis

2026-01-27

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$6 -> $24

AI Analysis

2026-01-27

upgrade

Reason

H.C. Wainwright adjusted the firm's price target on 60 Degrees Pharmaceuticals to $24 from $6 and keeps a Buy rating on the shares after accounting for the 1-for-4 reverse split conducted on January 20. The firm's price target is based on the value it assigns to 60 Degrees' lead asset, tafenoquine, for babesiosis in the U.S. only, noting that it does not include sales of Arakoda in its estimates yet due to a lack of visibility and current revenue generation in the malaria market.

H.C. Wainwright

Buy

initiated

$6

2025-11-14

Reason

H.C. Wainwright

Price Target

$6

2025-11-14

initiated

Buy

Reason

H.C. Wainwright assumed coverage of 60 Degrees Pharmaceuticals with a Buy rating and $6 price target. The firm says 60 Degrees is "flying under the radar with investors." Tafenoquine is a differentiated, FDA approved product that is already on the market and has demonstrated "impressive" initial clinical activity in babesiosis, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SXTP

Unlock Now

Valuation Metrics

The current forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP.O) is -0.14, compared to its 5-year average forward P/E of -0.88. For a more detailed relative valuation and DCF analysis to assess 60 Degrees Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.88

Current PE

-0.14

Overvalued PE

-0.02

Undervalued PE

-1.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

4.84

Current PS

1.47

Overvalued PS

10.59

Undervalued PS

-0.91

Financials

AI Analysis

Annual

Quarterly

Whales Holding SXTP

Trading Trends

People Also Watch

Frequently Asked Questions

What is 60 Degrees Pharmaceuticals Inc (SXTP) stock price today?

The current price of SXTP is 1.88 USD — it has decreased -2.59

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s business?

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

What is the price predicton of SXTP Stock?

Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s revenue for the last quarter?

60 Degrees Pharmaceuticals Inc revenue for the last quarter amounts to 256.28K USD, increased 75.42

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s earnings per share (EPS) for the last quarter?

60 Degrees Pharmaceuticals Inc. EPS for the last quarter amounts to -1.55 USD, decreased -183.78

How many employees does 60 Degrees Pharmaceuticals Inc (SXTP). have?

60 Degrees Pharmaceuticals Inc (SXTP) has 3 emplpoyees as of March 11 2026.

What is 60 Degrees Pharmaceuticals Inc (SXTP) market cap?

Today SXTP has the market capitalization of 3.28M USD.